Evidence map›Paper›PMID 34178879›Full record

ArticleFrontiers in pediatrics2021

Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I.

Nathan Grant, J Michael Taylor, Zach Plummer, Kasiani Myers, Thomas Burrow, Lori Luchtman-Jones, Anna Byars, Adrienne Hammill, Katie Wusick, Edward Smith and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Nathan GrantDivision of Pediatric Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
J Michael TaylorDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Zach PlummerDivision of Pediatric Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Kasiani MyersDivision of Hematology - Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Thomas BurrowDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Lori Luchtman-JonesDivision of Hematology - Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Anna ByarsDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Adrienne HammillDivision of Hematology - Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Katie WusickDivision of Hematology - Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Edward SmithDepartment of Neurosurgery, Boston Children's Hospital, Boston, MA, United States.
James LeachDepartment of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Sudhakar VadiveluDivision of Pediatric Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Cincinnati Children's Hospital Medical Center · USBoston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucopolysaccharidosis (MPS) type I is a rare lysosomal storage disorder caused by an accumulation of glycosaminoglycans (GAGs) resulting in multisystem disease. Neurological morbidity includes hydrocephalus, spinal cord compression, and cognitive decline. While many neurological symptoms have been described, stroke is not a widely-recognized manifestation of MPS I. Accordingly, patients with MPS I are not routinely evaluated for stroke, and there are no guidelines for managing stroke in patients with this disease. We report the case of a child diagnosed with MPS I who presented with overt stroke and repeated neurological symptoms with imaging findings for severe ventriculomegaly, infarction, and bilateral terminal carotid artery stenosis. Direct intracranial pressure evaluation proved negative for hydrocephalus. The patient was subsequently treated with cerebral revascularization and at a 3-year follow-up, the patient reported no further neurological events or new ischemia on cerebral imaging. Cerebral arteriopathy in patients with MPS I may be associated with GAG accumulation within the cerebrovascular system and may predispose patients to recurrent strokes. However, further studies are required to elucidate the etiology of cerebrovascular arteriopathy in the setting of MPS I. Although the natural history of steno-occlusive arteriopathy in patients with MPS I remains unclear, our findings suggest that cerebral revascularization is a safe treatment option that may mitigate the risk of future strokes and should be strongly considered within the overall management guidelines for patients with MPS I.

Indexed as

cerebral arteriopathycerebral revascularizationmucopolysaccharidosis Ipial synangiosisstrokeventriculomegaly

Identifiers

PMID34178879
PMCPMC8224401
OpenAlexW3166255771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.